Core Viewpoint - The launch of the Hong Kong Stock Connect Innovative Drug ETF by Harvest on August 7 has seen significant trading activity and premium, indicating strong investor interest in the innovative drug sector [1]. Group 1: Market Performance - The trading volume of the Hong Kong Stock Connect Innovative Drug ETF reached 166 million yuan on its first day, with a premium rate of 0.68% [1]. Group 2: Industry Analysis - Analysts suggest that the favorable fundamentals in the innovative drug sector, along with ongoing policy support, are driving investor interest in related assets [1]. - Dongwu Securities anticipates that with policy backing, the pharmaceutical industry is likely to achieve a win-win situation among medical services, insurance, and pharmaceuticals, enhancing the accessibility and affordability of innovative drugs and medical devices [1]. Group 3: Product Expansion - Harvest has been expanding its ETF offerings to help investors capture opportunities in the pharmaceutical sector, with the recent launch of the Hong Kong Stock Connect Innovative Drug ETF joining existing products like the Sci-Tech Pharmaceutical ETF and the Biopharmaceutical ETF [1].

Group 1 - The biopharmaceutical sector has become active again, with major ETFs in the sector seeing significant gains as the Shanghai Composite Index approached 3600 points [1] - Institutions are optimistic about the future of the pharmaceutical sector, citing upcoming events such as the World Lung Cancer Conference (WCLC) and the European Society for Medical Oncology (ESMO) as key points of interest [1] - The adjustment of medical insurance catalogs and the promotion of commercial insurance policies in the second half of the year are seen as important catalysts for the industry [1] Group 2 - Investors are encouraged to utilize pharmaceutical ETFs to efficiently capture investment opportunities in the sector, with the Biovaccine ETF and the Sci-Tech Pharmaceutical ETF leading in scale among peers [2] - The S&P Biotechnology ETF is noted as the first and only ETF product tracking the S&P Biotechnology Select Industry Index in the market [2] - The Pharmaceutical ETF is highlighted as a unique offering in the entire market [2]